Skip to main navigation

Sorrento Therapeutics

Search

Client Header Links

  • Who We Are
    • Overview
    • History
    • Leadership
    • Board of Directors
  • Research
    • Pipeline
    • Covid-19
    • Immuno-Oncology
    • Pain
    • Lymphatic Delivery System
    • Product Candidates
  • Manufacturing
  • Subsidiaries
  • Partnership
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • SEC FILINGS
    • Stock
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • Contact IR
  • Career
  • Contact

Presentations

Presentations

STI - Dividend FAQ
January 2023 Corporate Presentation
Sorrento STI-9167 and STI-9199 anti-Omicron Neutralization Antibody
Abivertinib November 2021
STI mRNA COVID Vaccine Program August 2021
Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain, at the 14th Annual Pain Therapeutics Summit held virtually from September 21, 2020

Tools

  • Print

    Print

  • Email Alerts

    Email Alerts

  • RSS Feeds

    RSS Feeds

  • Email Page

    Email Page

© 2023 Sorrento Therapeutics. All Rights Reserved.

Footer

    Terms of Use Privacy Policy DMCA Trademarks Linking Policy
logo

Client Header Links

  • Who We Are
    • Overview
    • History
    • Leadership
    • Board of Directors
  • Research
    • Pipeline
    • Covid-19
    • Immuno-Oncology
    • Pain
    • Lymphatic Delivery System
    • Product Candidates
  • Manufacturing
  • Subsidiaries
  • Partnership
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • SEC FILINGS
    • Stock
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • Contact IR
  • Career
  • Contact